Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing ...